Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Danicopan Add-on to Eculizumab in PNH Patients with Inadequate Response
NCT03472885Phase 2Completed
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2018
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of danicopan in paroxysmal nocturnal hemoglobinuria (PNH) (4 arms), sponsored by Alexion Pharmaceuticals. Primary endpoint: Change From Baseline In Hemoglobin At Week 24. Started May 2018; status: completed.
02
Drugs
danicopan
03
Conditions
paroxysmal nocturnal hemoglobinuria (PNH)
Beyond the preview
Go deeper on NCT03472885.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03472885.